doi: 10.3389/fnut.2025.1701661 Received 08 September 2025 Revised 10 November 2025 Accepted 04 December 2025 Published 05 January 2026 Volume 12 - 2025 Edited by Emanuele Micaglio, IRCCS San Donato Polyclinic, Italy Reviewed by Runzhe Xu, University of Texas Southwestern Medical Center, United States Husain Alkhaldy, King Khalid University, Saudi Arabia Updates Copyright 2026 de Carvalho, Akamine, Di Pietro, Frana, Oliveira and Lopes
The main difference is that Mounjaro (tirzepatide) has a dual action, targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors
Its formulation includes several active molecules
Keep in mind, though, studies comparing the two medications show higher rates of nausea and stomach upset with Mounjaro but everyone has different responses to medications, and your experience may differ from what was seen in studies
The spectrum of MASLD ranges from simple steatosiswhere fat accumulation causes minimal inflammationto metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), characterized by inflammation and liver cell damage that can progress to cirrhosis
Ginfort: Extracto de jengibre patentado con la mayor concentracin de gingeroides (26%), sin disolventes y con eficacia clnicamente probada